Nymirum, Inc.
Small molecule drug that binds toxic CUG repeat RNA to rescue myotonic dystrophy type 1
- Sector
- Biotech
- Headquarters
- ANN ARBOR, MI
- Founded
- 2009
- Latest Form D
- $550K, May 2009
- Total capital
- $2.9M
- Federal grants
- $2.4M
- 5 awards · 2015–2020
- Rank in peer group#460 of 514
- Private capital raised
- $550K
- 1 Form D · last May 2009
- 209 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 2 pending · first 2019
- Rank in peer group#142 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Developing Drug-like Small Molecules that Target Toxic Repeat RNAs to Alleviate Myotonic Dystrophy Type 1-derived Mis-Splicing$299K
- Federal grantHealth and Human S · Phase I · Targeting Exonuclease Resistant RNA to Develop Zika Virus Therapeutics$299K
- Federal grantHealth and Human S · Phase I · A Small Molecule Drug Discovery Platform to Target Cancer-Causing microRNAs.$298K
- Federal grantHealth and Human S · Phase II · An Automated RNA 3D Structure Determination System$729K
- Federal grantHealth and Human S · Phase II · An Automated RNA 3D Structure Determination System$729K
- Private capital raisedForm D · SEC · 1st filing$550K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#142 · top 28%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Edward ChandlerDirectorNamed in SEC Form D filings
- J.P. FairbankExecutive Officer, DirectorNamed in SEC Form D filings
- Michael PapeExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 4- GrantedSmall Molecule Binding Pockets In Nucleic AcidsUSPTOUS 10,522,239
- GrantedDevice and Methods for Analysis of Biomolecule Structure, Dynamics and ActivityUSPTOUS 10,228,337
- PendingDevice And Methods For Analysis Of Biomolecule Structure, Dynamics And ActivityUSPTOApplication PCTUS2013073330
Show all 4 patent records
- Small Molecule Binding Pockets In Nucleic AcidsDec 31, 2019 · US 10,522,239Granted
- Device and Methods for Analysis of Biomolecule Structure, Dynamics and ActivityMar 12, 2019 · US 10,228,337Granted
- Device And Methods For Analysis Of Biomolecule Structure, Dynamics And ActivityApplication PCTUS2013073330Pending
- Device and Methods for Analysis of Biomolecule Structure, Dynamics and ActivityApplication 61733784Pending
Related companies, and why
- Galera Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- REVERAGEN BIOPHARMA, INC.Similar federal contract value in Biotech · null in contracts
- SCARLESS LABORATORIES INCSimilar federal contract value in Biotech · null in contracts
- Covira SurgicalSimilar federal contract value in Biotech · null in contracts
- CHEMOSEN3D INCSimilar federal contract value in Biotech · null in contracts
- Talapo TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .